Pharmacogenomic identification of c-Myc/Max-regulated genes associated with cytotoxicity of artesunate towards human colon, ovarian and lung cancer cell lines

Molecules

Volumn 15, Issue 4, 2010, Pages 2886-2910

  Sertel, Serkan ^a,b,c   Eichhorn, Tolga ^b,c   Simon, Christian H ^a   Plinkert, Peter K ^a   Johnson, Steven W ^d   Efferth, Thomas ^b,c  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Artesunate (ART); Chemotherapeutic resistance; Clinical oncology; Expression profiling; Microarray; Pathway analysis

Indexed keywords

ARTEMISININ DERIVATIVE; ARTESUNATE; BASIC HELIX LOOP HELIX LEUCINE ZIPPER TRANSCRIPTION FACTOR; MAX PROTEIN, HUMAN; MYC PROTEIN; MYC PROTEIN, HUMAN;

ARTICLE; COLON TUMOR; DNA MICROARRAY; DRUG RESISTANCE; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IC 50; LUNG TUMOR; METABOLISM; OVARY TUMOR; PHARMACOGENETICS; TUMOR CELL LINE; TUMOR GENE;

ARTEMISININS; BASIC HELIX-LOOP-HELIX LEUCINE ZIPPER TRANSCRIPTION FACTORS; CELL LINE, TUMOR; COLONIC NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, NEOPLASM; HUMANS; INHIBITORY CONCENTRATION 50; LUNG NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OVARIAN NEOPLASMS; PHARMACOGENETICS; PROTO-ONCOGENE PROTEINS C-MYC;

EID: 77951851864     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules15042886     Document Type: Article

References (71)

1. Klayman, D.L. Qinghaosu (artemisinin): An antimalarial drug from China. Science 1985, 228, 1049-1055.
2. Tu, Y. The development of new antimalarial drugs: Qinghaosu and dihydro-qinghaosu. Chin. Med. J. (Engl.) 1999, 112 976-977.
3. Li, Y.; Wu, Y.L. How Chinese scientists discovered qinghaosu (artemisinin) and developed its derivatives? What are the future perspectives? Med. Trop. (Mars) 1998, 58, 9-12. (Pubitemid 128707810)
4. Efferth, T. Willmar Schwabe Award 2006: Antiplasmodial and antitumor activity of artemisininfrom bench to bedside. Planta Med. 2007, 73, 299-309.
5. Efferth, T.; Fu, Y.J.; Zu, Y.G.; Schwarz, G.; Konkimalla, V.S.; Wink, M. Molecular target-guided tumor therapy with natural products derived from traditional Chinese medicine. Curr. Med. Chem. 2007, 14, 2024-2032. (Pubitemid 47578160)
6. Efferth, T.; Giaisi, M.; Merling, A.; Krammer, P.H.; Li-Weber, M. Artesunate induces ROSmediated apoptosis in doxorubicin-resistant T leukemia cells. PLoS One 2007, 2, e693. (Pubitemid 351325407)
7. Efferth, T.; Li, P.C.; Konkimalla, V.S.; Kaina, B. From traditional Chinese medicine to rational cancer therapy. Trends Mol. Med. 2007, 13, 353-361. (Pubitemid 47126989)
8. Efferth, T.; Rucker, G.; Falkenberg, M.; Manns, D.; Olbrich, A.; Fabry, U.; Osieka, R. Detection of apoptosis in KG-1a leukemic cells treated with investigational drugs. Arzneimittelforschung 1996, 46, 196-200. (Pubitemid 26079152)
9. Efferth, T. Microarray-based prediction of cytotoxicity of tumor cells to cantharidin. Oncol. Rep. 2005, 13, 459-463. (Pubitemid 40248623)
10. Efferth, T.; Dunstan, H.; Sauerbrey, A.; Miyachi, H.; Chitambar, C.R. The anti-malarial artesunate is also active against cancer. Int. J. Oncol. 2001, 18, 767-773.
11. Efferth, T.; Briehl, M.M.; Tome, M.E. Role of antioxidant genes for the activity of artesunate against tumor cells. Int. J. Oncol. 2003, 23, 1231-1235.
12. Efferth, T. Mechanistic perspectives for 1,2,4-trioxanes in anti-cancer therapy. Drug Resist. Updat. 2005, 8, 85-97. (Pubitemid 40797959)
13. Berger, T.G.; Dieckmann, D.; Efferth, T.; Schultz, E.S.; Funk, J.O.; Baur, A.; Schuler, G. Artesunate in the treatment of metastatic uveal melanoma-first experiences. Oncol. Rep. 2005, 14, 1599-1603.
14. Efferth, T. Molecular pharmacology and pharmacogenomics of artemisinin and its derivatives in cancer cells. Curr. Drug Targets 2006, 7, 407-421. (Pubitemid 43744832)
15. Kelter, G.; Steinbach, D.; Konkimalla, V.B.; Tahara, T.; Taketani, S.; Fiebig, H.H.; Efferth, T. Role of transferrin receptor and the ABC transporters ABCB6 and ABCB7 for resistance and differentiation of tumor cells towards artesunate. PLoS One 2007, 2, e798. (Pubitemid 351386578)
16. Scherf, U.; Ross, D.T.; Waltham, M.; Smith, L.H.; Lee, J.K.; Tanabe, L.; Kohn, K.W.; Reinhold, W.C.; Myers, T.G.; Andrews, D.T.; Scudiero, D.A.; Eisen, M.B.; Sausville, E.A.; Pommier, Y.; Botstein, D.; Brown, P.O.; Weinstein, J.N. A gene expression database for the molecular pharmacology of cancer. Nat. Genet. 2000, 24, 236-244. (Pubitemid 30132190)
17. Staunton, J.E.; Slonim, D.K.; Coller, H.A.; Tamayo, P.; Angelo, M.J.; Park, J.; Scherf, U.; Lee, J.K.; Reinhold, W.O.; Weinstein, J.N.; Mesirov, J.P.; Lander, E.S.; Golub, T.R. Chemosensitivity prediction by transcriptional profiling. Proc. Natl. Acad. Sci. USA 2001, 98, 10787-10792. (Pubitemid 32878698)
18. Paull, K.D.; Lin, C.M.; Malspeis, L.; Hamel, E. Identification of novel antimitotic agents acting at the tubulin level by computer-assisted evaluation of differential cytotoxicity data. Cancer Res. 1992, 52, 3892-3900.
19. Leteurtre, F.; Kohlhagen, G.; Paull, K.D.; Pommier, Y. Topoisomerase II inhibition and cytotoxicity of the anthrapyrazoles DuP 937 and DuP 941 (Losoxantrone) in the National Cancer Institute preclinical antitumor drug discovery screen. J. Nat. Cancer Inst. 1994, 86, 1239-1244. (Pubitemid 24253700)
20. Shi, L.M.; Myers, T.G.; Fan, Y.; O'Connor, P.M.; Paull, K.D.; Friend, S.H.; Weinstein, J.N. Mining the National Cancer Institute Anticancer Drug Discovery Database: cluster analysis of ellipticine analogs with p53-inverse and central nervous system-selective patterns of activity. Mol. Pharmacol. 1998, 53, 241-251. (Pubitemid 28099734)
21. Efferth, T.; Gebhart, E.; Ross, D.D.; Sauerbrey, A. Identification of gene expression profiles predicting tumor cell response to L-alanosine. Biochem. Pharmacol. 2003, 66, 613-621. (Pubitemid 37281280)
22. Efferth, T.; Olbrich, A.; Bauer, R. mRNA expression profiles for the response of human tumor cell lines to the antimalarial drugs artesunate, arteether, and artemether. Biochem. Pharmacol. 2002, 64, 617-623.
23. Harris, E.H.; Burkhart, B.D.; Gillham, N.W.; Boynton, J.E. Antibiotic resistance mutations in the chloroplast 16S and 23S rRNA genes of Chlamydomonas reinhardtii: Correlation of genetic and physical maps of the chloroplast genome. Genetics 1989, 123, 281-292.
24. Higgins, C.F. Multiple molecular mechanisms for multidrug resistance transporters. Nature 2007, 446, 749-757. (Pubitemid 46582024)
25. Efferth, T. The human ATP-binding cassette transporter genes: From the bench to the bedside. Curr. Mol. Med. 2001, 1, 45-65. (Pubitemid 33772969)
26. Gillet, J.P.; Efferth, T.; Remacle, J. Chemotherapy-induced resistance by ATP-binding cassette transporter genes. Biochim. Biophys. Acta 2007, 1775, 237-262. (Pubitemid 46899341)
27. Kool, M.; van der Linden, M.; de Haas, M.; Scheffer, G.L.; de Vree, J.M.; Smith, A.J.; Jansen, G.; Peters, G.J.; Ponne, N.; Scheper, R.J.; Elferink, R.P.; Baas, F.; Borst, P. MRP3, an organic anion transporter able to transport anti-cancer drugs. Proc. Nat. Acad. Sci. USA 1999, 96, 6914-6919. (Pubitemid 29274984)
28. Efferth, T.; Sauerbrey, A.; Olbrich, A.; Gebhart, E.; Rauch, P.; Weber, H.O.; Hengstler, J.G.; Halatsch, M.E.; Volm, M.; Tew, K.D.; Ross, D.D.; Funk, J.O. Molecular modes of action of artesunate in tumor cell lines. Mol. Pharmacol. 2003, 64, 382-394. (Pubitemid 36910002)
29. Sertel, S.; Eichhorn, T.; Sieber, S.; Sauer, A.; Weiss, J.; Plinkert, P.K.; Efferth, T. Factors determining sensitivity or resistance of tumor cell lines towards artesunate. Chem. Biol. Interact. 2010, 185, 42-52.
30. Grant, S.; Qiao, L.; Dent, P. Roles of ERBB family receptor tyrosine kinases, and downstream signaling pathways, in the control of cell growth and survival. Front. Biosci. 2002, 7, d376-d389.
31. McCubrey, J.A.; Steelman, L.S.; Chappell, W.H.; Abrams, S.L.; Wong, E.W.; Chang, F.; Lehmann, B.; Terrian, D.M.; Milella, M.; Tafuri, A.; Stivala, F.; Libra, M.; Basecke, J.; Evangelisti, C.; Martelli, A.M.; Franklin, R.A. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim. Biophys. Acta 2007, 1773, 1263-1284. (Pubitemid 47125967)
32. Konkimalla, V.B.; McCubrey, J.A.; Efferth, T. The role of downstream signaling pathways of the epidermal growth factor receptor for Artesunate's activity in cancer cells. Curr. Cancer Drug Targets 2009, 9, 72-80.
33. Muller, P.A.; Klomp, L.W. ATOX1: a novel copper-responsive transcription factor in mammals? Int. J. Biochem. Cell Biol. 2009, 41, 1233-1236.
34. Boal, A.K.; Rosenzweig, A.C. Crystal structures of cisplatin bound to a human copper chaperone. J. Am. Chem. Soc. 2009, 131, 14196-14197.
35. Guay, D.; Evoy, A.A.; Paquet, E.; Garand, C.; Bachvarova, M.; Bachvarov, D.; Lebel, M. The strand separation and nuclease activities associated with YB-1 are dispensable for cisplatin resistance but overexpression of YB-1 in MCF7 and MDA-MB-231 breast tumor cells generates several chemoresistance signatures. Int. J. Biochem. Cell Biol. 2008, 40, 2492-2507.
36. Tay, W.L.; Yip, G.W.; Tan, P.H.; Matsumoto, K.; Yeo, R.; Ng, T.P.; Kumar, S.D.; Tsujimoto, M.; Bay, B.H. Y-Box-binding protein-1 is a promising predictive marker of radioresistance and chemoradioresistance in nasopharyngeal cancer. Mod. Pathol. 2009, 22, 282-290.
37. Shibahara, K.; Sugio, K.; Osaki, T.; Uchiumi, T.; Maehara, Y.; Kohno, K.; Yasumoto, K.; Sugimachi, K.; Kuwano, M. Nuclear expression of the Y-box binding protein, YB-1, as a novel marker of disease progression in non-small cell lung cancer. Clin. Cancer Res. 2001, 7, 3151-3155. (Pubitemid 32963838)
38. Gessner, C.; Woischwill, C.; Schumacher, A.; Liebers, U.; Kuhn, H.; Stiehl, P.; Jurchott, K.; Royer, H.D.; Witt, C.; Wolff, G. Nuclear YB-1 expression as a negative prognostic marker in nonsmall cell lung cancer. Eur. Respir. J. 2004, 23, 14-19. (Pubitemid 38088490)
39. Gottesman, M.M.; Pastan, I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Ann. Rev. Biochem. 1993, 62, 385-427. (Pubitemid 23237876)
40. Huang, J.; Tan, P.H.; Li, K.B.; Matsumoto, K.; Tsujimoto, M.; Bay, B.H. Y-box binding protein, YB-1, as a marker of tumor aggressiveness and response to adjuvant chemotherapy in breast cancer. Int. J. Oncol. 2005, 26, 607-613.
41. Plebuch, M.; Soldan, M.; Hungerer, C.; Koch, L.; Maser, E. Increased resistance of tumor cells to daunorubicin after transfection of cDNAs coding for anthracycline inactivating enzymes. Cancer Lett. 2007, 255, 49-56. (Pubitemid 47212606)
42. Penning, T.M. Dihydrodiol dehydrogenase and its role in polycyclic aromatic hydrocarbon metabolism. Chem. Biol. Interact. 1993, 89, 1-34.
43. Wang, H.W.; Lin, C.P.; Chiu, J.H.; Chow, K.C.; Kuo, K.T.; Lin, C.S.; Wang, L.S. Reversal of inflammation-associated dihydrodiol dehydrogenases (AKR1C1 and AKR1C2) overexpression and drug resistance in nonsmall cell lung cancer cells by wogonin and chrysin. Int. J. Cancer 2007, 120, 2019-2027.
44. Sreerama, L.; Sladek, N.E. Primary breast tumor levels of suspected molecular determinants of cellular sensitivity to cyclophosphamide, ifosfamide, and certain other anticancer agents as predictors of paired metastatic tumor levels of these determinants. Rational individualization of cancer chemotherapeutic regimens. Cancer Chemother. Pharmacol. 2001, 47, 255-262. (Pubitemid 32640761)
45. Hu, G.; Chong, R.A.; Yang, Q.; Wei, Y.; Blanco, M.A.; Li, F.; Reiss, M.; Au, J.L.; Haffty, B.G.; Kang, Y. MTDH activation by 8q22 genomic gain promotes chemoresistance and metastasis of poor-prognosis breast cancer. Cancer Cell 2009, 15, 9-20.
46. Gilmore, T.D. Introduction to NF-kappaB: Players, pathways, perspectives. Oncogene 2006, 25, 6680-6684.
47. Bharti, A.C.; Aggarwal, B.B. Nuclear factor-kappa B and cancer: Its role in prevention and therapy. Biochem. Pharmacol. 2002, 64, 883-888. (Pubitemid 35238030)
48. Kellen, J.A. Molecular interrelationships in multidrug resistance (review). Anticancer Res. 1994, 14, 433-435. (Pubitemid 24176783)
49. Lonning, P.E. Genes causing inherited cancer as beacons to identify the mechanisms of chemoresistance. Trends Mol. Med. 2004, 10, 113-118.
50. Daum, G. Lipid Metabolism and Membrane Biogenesis; Springer-Verlag: Berlin-Heidelberg, Germany, 2004.
51. Cornwell, M.M.; Safa, A.R.; Felsted, R.L.; Gottesman, M.M.; Pastan, I. Membrane vesicles from multidrug-resistant human cancer cells contain a specific 150- to 170-kDa protein detected by photoaffinity labeling. Proc. Nat. Acad. Sci. USA 1986, 83, 3847-3850.
52. Dietel, M.; Arps, H.; Lage, H.; Niendorf, A. Membrane vesicle formation due to acquired mitoxantrone resistance in human gastric carcinoma cell line EPG85-257. Cancer Res. 1990, 50, 6100-6106. (Pubitemid 20331427)
53. Hennessy, B.T.; Smith, D.L.; Ram, P.T.; Lu, Y.; Mills, G.B. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat. Rev. Drug Discov. 2005, 4, 988-1004.
54. Zhang, L.; Huang, J.; Yang, N.; Greshock, J.; Liang, S.; Hasegawa, K.; Giannakakis, A.; Poulos, N.; O'Brien-Jenkins, A.; Katsaros, D.; Butzow, R.; Weber, B.L.; Coukos, G. Integrative genomic analysis of phosphatidylinositol 3'-kinase family identifies PIK3R3 as a potential therapeutic target in epithelial ovarian cancer. Clin. Cancer Res. 2007, 13, 5314-5321. (Pubitemid 47510355)
55. Humtsoe, J.O.; Kramer, R.H. Differential epidermal growth factor receptor signaling regulates anchorage-independent growth by modulation of the PI3K/AKT pathway. Oncogene 2009, 29, 1214-1226.
56. Chen, Y.X.; Wang, Y.; Fu, C.C.; Diao, F.; Song, L.N.; Li, Z.B.; Yang, R.; Lu, J. Dexamethasone enhances cell resistance to chemotherapy through increasing adhesion to extracellular matrix in human ovarian cancer cells. Endocr. Relat. Cancer 2009, 17, 39-50.
57. Samarakoon, R.; Higgins, C.E.; Higgins, S.P.; Higgins, P.J. TGF-beta1-Induced Expression of the Poor Prognosis SERPINE1/PAI-1 Gene Requires EGFR Signaling: A New Target for Anti-EGFR Therapy. J. Oncol. 2009, 2009, 342391.
58. Maglich, J.M.; Stoltz, C.M.; Goodwin, B.; Hawkins-Brown, D.; Moore, J.T.; Kliewer, S.A. Nuclear pregnane x receptor and constitutive androstane receptor regulate overlapping but distinct sets of genes involved in xenobiotic detoxification. Mol. Pharmacol. 2002, 62, 638-646. (Pubitemid 36329382)
59. Traber, M.G. Vitamin E, nuclear receptors and xenobiotic metabolism. Arch. Biochem. Biophys. 2004, 423, 6-11.
60. Konkimalla, V.B.; Blunder, M.; Korn, B.; Soomro, S.A.; Jansen, H.; Chang, W.; Posner, G.H.; Bauer, R.; Efferth, T. Effect of artemisinins and other endoperoxides on nitric oxide-related signaling pathway in RAW 264.7 mouse macrophage cells. Nitric Oxide 2008, 19, 184-191.
61. Efferth, T.; Benakis, A.; Romero, M.R.; Tomicic, M.; Rauh, R.; Steinbach, D.; Hafer, R.; Stamminger, T.; Oesch, F.; Kaina, B.; Marschall, M. Enhancement of cytotoxicity of artemisinins toward cancer cells by ferrous iron. Free Radical Biol. Med. 2004, 37, 998-1009. (Pubitemid 39164582)
62. Cody, G.D.; Boctor, N.Z.; Filley, T.R.; Hazen, R.M.; Scott, J.H.; Sharma, A.; Yoder, H.S., Jr. Primordial carbonylated iron-sulfur compounds and the synthesis of pyruvate. Science 2000, 289, 1337-1340. (Pubitemid 30656047)
63. Lu, C.W.; Lin, S.C.; Chen, K.F.; Lai, Y.Y.; Tsai, S.J. Induction of pyruvate dehydrogenase kinase-3 by hypoxia-inducible factor-1 promotes metabolic switch and drug resistance. J. Biol. Chem. 2008, 283, 28106-28114.
64. Chen, H.H.; Zhou, H.J.; Wang, W.Q.; Wu, G.D. Antimalarial dihydroartemisinin also inhibits angiogenesis. Cancer Chemother. Pharmacol. 2004, 53, 423-432.
65. Dell'Eva, R.; Pfeffer, U.; Vene, R.; Anfosso, L.; Forlani, A.; Albini, A.; Efferth, T. Inhibition of angiogenesis in vivo and growth of Kaposi's sarcoma xenograft tumors by the anti-malarial artesunate. Biochem. Pharmacol. 2004, 68, 2359-2366. (Pubitemid 39535108)
66. Roberts, D.; Schick, J.; Conway, S.; Biade, S.; Laub, P.B.; Stevenson, J.P.; Hamilton, T.C.; O'Dwyer, P.J.; Johnson, S.W. Identification of genes associated with platinum drug sensitivity and resistance in human ovarian cancer cells. Br. J. Cancer 2005, 92, 1149-1158. (Pubitemid 40546683)
67. Johnson, S.W.; Swiggard, P.A.; Handel, L.M.; Brennan, J.M.; Godwin, A.K.; Ozols, R.F.; Hamilton, T.C. Relationship between platinum-DNA adduct formation and removal and cisplatin cytotoxicity in cisplatin-sensitive and -resistant human ovarian cancer cells. Cancer Res. 1994, 54, 5911-5916.
68. Hansen, M.B.; Nielsen, S.E.; Berg, K. Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J. Immunol. Methods 1989, 119, 203-210.
69. Chomczynski, P.; Sacchi, N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 1987, 162, 156-159. (Pubitemid 17064313)
70. Chomczynski, P.; Mackey, K. Substitution of chloroform by bromo-chloropropane in the singlestep method of RNA isolation. Anal. Biochem. 1995, 225, 163-164.
71. Paull, K.D.; Shoemaker, R.H.; Hodes, L.; Monks, A.; Scudiero, D.A.; Rubinstein, L.; Plowman, J.; Boyd, M.R. Display and analysis of patterns of differential activity of drugs against human tumor cell lines: Development of mean graph and COMPARE algorithm. J. Nat. Cancer Inst. 1989, 81, 1088-1092. (Pubitemid 19175145)